Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash from Operations (2020 - 2025)

Bolt Biotherapeutics' Cash from Operations history spans 6 years, with the latest figure at 9732000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 30.32% year-over-year to 9732000.0; the TTM value through Sep 2025 reached 47124000.0, up 22.9%, while the annual FY2024 figure was 61289000.0, 11.85% up from the prior year.
  • Cash from Operations for Q3 2025 was 9732000.0 at Bolt Biotherapeutics, down from 9597000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3986000.0 in Q2 2021 and bottomed at 24314000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 16142000.0 (2024), against an average of 15635684.21.
  • The largest annual shift saw Cash from Operations surged 67.5% in 2021 before it tumbled 421.5% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 17794000.0 in 2021, then decreased by 0.89% to 17952000.0 in 2022, then increased by 20.54% to 14265000.0 in 2023, then decreased by 1.16% to 14430000.0 in 2024, then skyrocketed by 32.56% to 9732000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Cash from Operations are 9732000.0 (Q3 2025), 9597000.0 (Q2 2025), and 13365000.0 (Q1 2025).